Columbia Study Examines ADHD's Role in SmokingNovember 16, 2006New York - Are you easily forgetful, distracted, impulsive or fidgety? Do you find that smoking helps you alleviate these symptoms? Columbia University Medical Center researchers are investigating whether these most common symptoms of attention deficit hyperactivity disorders (ADHD) could be causing people to smoke. If that is the case, will treatment for ADHD combined with the standard treatment to help people quit smoking - the patch with counseling - increase the quit rates for smokers trying to quit? Lirio S. Covey, Ph.D., director of the Smoking Cessation Program at Columbia University Medical Center, is trying to find out.
Covey and her colleagues are recruiting smokers who have been diagnosed with ADHD or who may have symptoms of ADHD but have not yet been diagnosed, to be part of a study that will help them quit smoking. Approximately 7-8 million adults in the U.S. have ADHD. Smoking is twice as common in this population as in the general population. Research has shown that most smoking in the U.S. occurs among people who have psychiatric conditions, such as alcohol or drug abuse, major depression, anxiety and ADHD. One line of research has shown that smokers with these conditions "self-medicate" their symptoms with nicotine, the primary addictive substance in tobacco. Participants in the study will receive the nicotine patch, behavioral counseling, and a drug approved by the Food and Drug Administration for the treatment of ADHD called methylphenidate (brand name CONCERTA®). Because methylphenidate and nicotine act on the brain in a similar way, the premise is that treatment with methylphenidate when trying to quit smoking may reduce symptoms of ADHD while also reducing tobacco withdrawal symptoms. These benefits together may lead to increased success in quitting. "Nicotine seems to quell the symptoms for ADHD, but unfortunately the other ingredients in cigarettes and the act of taking in nicotine through the lungs makes it very bad for you," says Dr. Covey. "Our hope is that we can affect some of the same receptors and transmitters activated by nicotine with this ADHD treatment so that smokers are relieved from their ADHD symptoms and are less likely to light up." The Smoking Cessation Program at Columbia University Medical Center is seeking participants aged 18- to 55-years-old to enroll in this study. The study, being run out of the New York State Psychiatric Institute located on the CUMC campus on the upper west side of Manhattan, is one of six sites funded by the National Institute on Drug Abuse (NIDA) to carry out this study in the U.S. Participation is conditional upon completion of screening procedures including assessments to determine the presence of ADHD and the smoker's level of cigarette use. Qualified participants will be randomized to receive either methylphenidate or an identical-looking placebo or sugar pill. All participants will receive the nicotine patch and 11 weeks of behavioral counseling. Reimbursement for time and travel will be offered to research participants. For more information or to participate in the study, call the Smoking Cessation Program at Columbia University Medical Center at (212) 543-5905. The center is located at 1051 Riverside Drive in the Washington Heights community of northern Manhattan. All inquiries about the study will be kept confidential. Relevant Stats: -Cigarette smoking is the number one health problem in the U.S. -About a quarter of New Yorkers still light up daily. -An estimated 450,000 Americans lose their lives as a result of smoking related disease. Columbia University Medical Center | |||||||||||||||||||||
|
Related ADHD News Articles Barrow scientists work their magic Two neuroscientists at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center are turning magic tricks into science. APA task force recommends dissemination of evidence-based practice An estimated 15 million American children are diagnosed with a mental disorder, but only about a quarter of them are getting appropriate treatment based on scientific evidence. Innovative program focuses on improved care for children with ADHD An innovative program is helping busy primary care physicians improve the care they provide for school-aged children with Attention-Deficit/Hyperactivity Disorder (ADHD), according to a study led by researchers at Cincinnati Children's Hospital Medical Center and published in the July edition of Pediatrics. Did the gene for ADHD help our nomadic ancestors? An ADHD-associated version of the human gene DRD4 is linked to better health among nomadic tribesmen, but may cause malnourishment in their settled cousins, according to new research by a team directed by an anthropologist at the University of Wisconsin-Milwaukee (UWM). PET imaging focuses on medication's purported ability to improve mental performance Concerned by the growing numbers of people using stimulant medications such as methylphenidate (MP)-either legally or illegally-to improve attention and focus, researchers used positron emission tomography (PET) imaging with the radiotracer fluorodeoxyglucose (FDG) to assess the effects of the drug on brain function in the normal human brain. Knowing looks: Using gaze aversion to tell when children are learning People use eye contact in a variety of ways every minute of every day but how often do you find yourself staring into space with concentrating on an issue or problem? Psychologists now know that people who are carrying out a complex task tend to look away from anyone else who is nearby. They refer to it as 'gaze aversion'. Report confirms increased risk of smoking, substance abuse in bipolar adolescents A study from the Massachusetts General Hospital (MGH) supports previous reports that adolescents with bipolar disorder are at increased risk for smoking and substance abuse. Children's diet not the main cause of ADHD Food may not be the major cause of hyperactivity in children. Genetics, brain function and parental actions such as smoking may be just as important. A trial of removing food additives should be considered for hyperactive children A properly supervised trial eliminating colours and preservatives from the diet of hyperactive children should considered a part of the standard treatment, says an editorial in this week's BMJ. Phase III pivotal results presented of VYVANSE to treat ADHD in adults Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints. More ADHD News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||